An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 21 Jan 2019 Status changed from not yet recruiting to recruiting.
- 17 Dec 2018 Planned initiation date changed from 26 Nov 2018 to 21 Dec 2018.
- 27 Nov 2018 New trial record